Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$24.84 USD
-0.04 (-0.16%)
Updated May 24, 2024 03:59 PM ET
After-Market: $24.85 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 161 - 180 ( 278 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With Additional Program Update Intellia Poised to Continue Winning Streak; Reiterate Buy and PT at $171
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One and Done - In Vivo Gene Editing with CRISPR/Cas9 Works. PT to $110.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Are Bullish On the Interim TTR Data Report At the June 26th PNS Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Forms NewCo With Partners To Accelerate Novel CAR-T Programs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Gives Birth to an Adolescent CAR-T Company With Superior Genetics; Reiterate Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage of Intellia; Poised For Success With One and Done- CRISPR/Cas9 Cures for Genetic Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia at the American Society of Gene and Cell Therapy Meeting
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Financials; AT The Ready for ATTR Data Mid-year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Data Readout for ATTR Slated for Mid-2021. Rating Buy. PT to $80.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T